To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Recruiting

Phase 3

VadadustatTo Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Sponsor:

Akebia Therapeutics

Code:

NCT06901505

Conditions

Anemia of Chronic Kidney Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Erythropoiesis-Stimulating Agent (ESA)

Vadadustat

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-30. This information was provided to ClinicalTrials.gov by Akebia Therapeutics on 2025-08-20.